PSCI launches progressive position on the use of Horseshoe Crabs
A quarterly series of articles about responsible supply chain management from the PSCI.
Horseshoe Crabs are an ancient group of crab species that have been around for more than 400 million years. Their blood has the remarkable property of indicating certain types of endotoxins.
For this reason, it has been harvested by the medical and pharma industries to use as a test for these harmful compounds. Endotoxin testing using approved methods is a key demand of the regulators who authorise pharmaceutical development and manufacturing.
While this process does not require the death of the animal, there are still questions over possible animal welfare, biodiversity, and sustainability impacts from the collection of these materials from populations of wild crabs. Of the three affected species of Horseshoe Crabs across the USA and Asia, one Asian species is listed as endangered, with concerns over the other Asian species where data is deficient.
The connection between the Horseshoe Crab species and the pharmaceutical sector does highlight the importance of biodiversity for human health and acts an excellent example of interdependence between medicine and biodiversity. It also illustrates the complexity of biodiversity-related sourcing in a regulated industry.
However, it also emphasizes the need for the industry to take an active position, and so the Pharmaceutical Supply Chain Initiative (PSCI) has launched our progressive position paper on what we believe to be good practice for the use of Horseshoe Crab blood within the pharmaceutical industry.
“The PSCI is releasing this position paper to encourage our members to protect the endangered species, seek out alternatives to these materials, and to adopt an intentional approach to sourcing where it remains necessary. Our commitment is to work together now, to drive this transition towards a long-term sustainable position and to play our part in protecting these remarkable species.”
– A spokesperson for the PSCI.
Representing 75 of the world’s largest pharmaceutical companies, the PSCI will encourage its members to commit to no further collection from endangered species, minimising the use of these materials, and sharing information to understand the surrounding animal welfare and conservation questions.
While this paper is not a membership requirement for the PSCI, it does outline the organisation’s views on good practice as it continues its commitment to the protection of all endangered species. It is important the industry has a strategy for reducing its dependence on Horseshoe Crab-derived products, and the PSCI is committed to working with its members to facilitate their progress and report the position across the whole industry.
Read more via the button below.
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients.
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Since the onset of the COVID-19 pandemic, the innovative potential of mRNA vaccines and therapeutics has raised questions regarding their manufacturing, packaging, and storage/transportation. Learn about how the pharmaceutical supply chain is meet...
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Novavax, developers behind the Matrix-M adjuvant, have entered into an agreement with the Bill and Melinda Gates Medical Research Institute to provide the adjuvant in preclinical vaccine research.
The life science service and instrument provider have opened their new Singapore-based steriles drug manufacturing facility with the goal of bringing increased development and manufacturing capabilities for critical medicines to the APAC region.
News Medicines for All receive $18.7 million grant for expansion of global access to lifesaving medicationFunded by the Bill & Melinda Gates Foundation, the Virginia Commonwealth University-based research-related institute will use the grant to expand on its current capabilities of bringing lifesaving medications around the world, as well as working on 14 ...
Merck and XtalPi Inc. collaborate on an AI-powered technology platform to predict the crystal morphologies of diabetic medication metformin HCl, validated by wet-lab experiments conducted with Merck’s expertise, in a ‘digital-first’ a...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance